CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity
Filppu, Pauliina; Ramanathan, Jayendrakishore Tanjore; Granberg, Kirsi J.; Gucciardo, Erika; Haapasalo, Hannu; Lehti, Kaisa; Nykter, Matti; Le Joncour, Vadim; Laakkonen, Pirjo (2021-05-10)
Lataukset:
Filppu, Pauliina
Ramanathan, Jayendrakishore Tanjore
Granberg, Kirsi J.
Gucciardo, Erika
Haapasalo, Hannu
Lehti, Kaisa
Nykter, Matti
Le Joncour, Vadim
Laakkonen, Pirjo
10.05.2021
e141486
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202106085754
https://urn.fi/URN:NBN:fi:tuni-202106085754
Kuvaus
Peer reviewed
Tiivistelmä
Glioma stem cells (GSCs) drive propagation and therapeutic resistance of glioblastomas, the most aggressive diffuse brain tumors. However, the molecular mechanisms that maintain the stemness and promote therapy resistance remain poorly understood. Here we report CD109/STAT3 axis as crucial for the maintenance of stemness and tumorigenicity of GSCs and as a mediator of chemoresistance. Mechanistically, CD109 physically interacts with glycoprotein 130 to promote activation of the IL-6/STAT3 pathway in GSCs. Genetic depletion of CD109 abolished the stemness and self-renewal of GSCs and impaired tumorigenicity. Loss of stemness was accompanied with a phenotypic shift of GSCs to more differentiated astrocytic-like cells. Importantly, genetic or pharmacologic targeting of CD109/STAT3 axis sensitized the GSCs to chemotherapy, suggesting that targeting CD109/STAT3 axis has potential to overcome therapy resistance in glioblastoma.
Kokoelmat
- TUNICRIS-julkaisut [16944]